EUVIMEDEUVIMED entdecken
Crossref

Inhibition of tumor cell macropinocytosis driver DHODH reverses immunosuppression and overcomes anti-PD1 resistance

Yujia Wang, Yangyang Chai, Yanfang Liu, Xinpeng Liu, Yunkai Zhang, Zhen Yang, Shenhui Yin, Jianhua Luo, Zhiqing Li, Yan Gu, Yizhi Yu, Xuetao Cao

Immunity · 2025-10 · 58 (10) · 2456-2471.e6

DOI: 10.1016/j.immuni.2025.07.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, 2025-10. Verfasst von Yujia Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sci…. Hauptthemen laut MEDLINE: Pinocytosis, Programmed Cell Death 1 Receptor, Drug Resistance, Neoplasm, Oxidoreductases Acting on CH-CH Group Donors. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Chinese Academy of Medical Sciences Initiative for Innovative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor cells' macropinocytosis sustains their growth under nutrient-limiting conditions. However, the metabolic regulation of cancer macropinocytosis in immune escape and its effect on immunotherapy remain unclear. Through the metabolism compound library and genome-wide CRISPR-Cas9 screenings, we identified dihydroorotate dehydrogenase (DHODH) as an essential driver of tumor cell macropinocytosis. DHODH sustained O-GlcNAcylation of the macropinocytic mediator neuropilin-1 (NRP1) and its membrane localization, mediating tumor cell macropinocytosis. Moreover, the DHODH-NRP1 axis-driven macropinocytosis increased intracellular amounts of lysine and tryptophan, which promoted glutarylation of the transcription factor class II transactivator (CIITA) to repress cancer cell major histocompatibility complex class II (MHC class II) expression. Pharmacological inhibition or genetic deletion of tumor cell-expressed DHODH potently recruited more immune cell infiltration and activated antitumor immunity in vivo, overcoming anti-programmed cell death protein 1 (PD1) resistance. High expression of DHODH and NRP1 in human breast and lung cancer tissues predicted patients' poor prognosis. Therefore, targeting DHODH to inhibit tumor cell macropinocytosis provides a potential approach to reverse immunosuppression for improving cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PinocytosisProgrammed Cell Death 1 ReceptorDrug Resistance, NeoplasmOxidoreductases Acting on CH-CH Group DonorsNeoplasmsHumansAnimalsMiceDihydroorotate DehydrogenaseCell Line, TumorFemaleNeuropilin-1Tumor EscapeImmunotherapy

Stichwörter der Autor:innen

O-GlcNAcylationcancer immunotherapydihydroorotate dehydrogenaseglutarylationmacropinocytosisneuropilin-1, MHC class IIpyrimidine metabolism

Substanzen

Programmed Cell Death 1 ReceptorDihydroorotate DehydrogenaseNeuropilin-1PDCD1 protein, humanOxidoreductases Acting on CH-CH Group Donors

Autor:innen und Institutionen

  • Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100005, China; National Key Laboratory of Immunity and…
  • Department of Immunology, Center for Immunotherapy, Institute of Basic Medical Sciences, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100005, China.
  • Department of Pathology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
  • Institute of Immunology, College of Life Sciences, Nankai University, Tianjin 300071, China.
  • National Key Laboratory of Immunity and Inflammation, Institute of Immunology, Naval Medical University, Shanghai 200433, China.

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Chinese Academy of Medical Sciences Initiative for Innovative Medicine
  • National Postdoctoral Program for Innovative Talents

Zitieren

APA

Wang, Y., Chai, Y., Liu, Y., Liu, X., Zhang, Y., Yang, Z., Yin, S., Luo, J., Li, Z., Gu, Y., Yu, Y., & Cao, X. (2025). Inhibition of tumor cell macropinocytosis driver DHODH reverses immunosuppression and overcomes anti-PD1 resistance. Immunity, 58(10), 2456-2471.e6. https://doi.org/10.1016/j.immuni.2025.07.013

Vancouver

Wang Y, Chai Y, Liu Y, Liu X, Zhang Y, Yang Z, et al. Inhibition of tumor cell macropinocytosis driver DHODH reverses immunosuppression and overcomes anti-PD1 resistance. Immunity. 2025;58(10):2456-2471.e6. doi:10.1016/j.immuni.2025.07.013

BibTeX
@article{Wang2025,
  author = {Wang, Yujia and Chai, Yangyang and Liu, Yanfang and Liu, Xinpeng and Zhang, Yunkai and Yang, Zhen and Yin, Shenhui and Luo, Jianhua and Li, Zhiqing and Gu, Yan and Yu, Yizhi and Cao, Xuetao},
  title = {Inhibition of tumor cell macropinocytosis driver DHODH reverses immunosuppression and overcomes anti-PD1 resistance},
  journal = {Immunity},
  year = {2025},
  volume = {58},
  number = {10},
  pages = {2456--2471.e6},
  doi = {10.1016/j.immuni.2025.07.013}
}
Kostenlos starten →